The Therapeutic Approaches for Hepatitis C Virus: Protease Inhibitors and Polymerase Inhibitors

por Kwo, Paul Y., Vinayek, Rakesh
Publicado 2011

Toward Elimination of Hepatitis C Infection: How Best to Address Gaps in the Cascade of Care?

por Prabhakar, Vijay, Kwo, Paul Y.
Publicado 2019

Current and future strategies for the treatment of chronic hepatitis C

por Alshuwaykh, Omar, Kwo, Paul Y.
Publicado 2021

HCV treatment in 2020: How to translate highly effective therapies into elimination strategies

por Alshuwaykh, Omar, Kwo, Paul Y
Publicado 2020

Resolution of Crizotinib-Associated Fulminant Hepatitis following Cessation of Treatment

por Charville, Gregory W., Padda, Sukhmani K., Sibley, Richard K., Puthillath, Ajithkumar, Kwo, Paul Y.
Publicado 2018

Immunoglobulin G4-Seronegative Autoimmune Cholangiopathy With Pancreatic and Hepatic Involvement Mimicking as Primary Sclerosing Cholangitis

por Achalu, Sudharshan, Berry, Rani, Wei, Mike T., Banerjee, Subhas, Ghanouni, Pejman, Kambham, Neeraja, Kwo, Paul Y.
Publicado 2023

Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort an...

por Kwo, Paul Y., Puenpatom, Amy, Zhang, Zuoyi, Hui, Siu L., Kelley, Andrea A., Muschi, David
Publicado 2019

The Ribavirin Pregnancy Registry: An Interim Analysis of Potential Teratogenicity at the Mid-Point of Enrollment

por Sinclair, Susan M., Jones, Judith K., Miller, Richard K., Greene, Michael F., Kwo, Paul Y., Maddrey, Willis C.
Publicado 2017

Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial

por Wyles, David, Poordad, Fred, Wang, Stanley, Alric, Laurent, Felizarta, Franco, Kwo, Paul Y., Maliakkal, Benedict, Agarwal, Kosh, Hassanein, Tarek, Weilert, Frank, Lee, Samuel S., Kort, Jens, Lovell, Sandra S., Liu, Ran, Lin, Chih‐Wei, Pilot‐Matias, Tami, Krishnan, Preethi, Mensa, Federico J.
Publicado 2018

Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies

por Yao, Betty B., Fredrick, Linda M., Schnell, Gretja, Kowdley, Kris V., Kwo, Paul Y., Poordad, Fred, Nguyen, Kinh, Lee, Samuel S., George, Christophe, Wong, Florence, Gane, Edward, Abergel, Armand, Spearman, Catherine W., Nguyen, Tuan, Hung Le, Manh, Pham, Thuy TT., Mensa, Federico, Asselah, Tarik
Publicado 2020

Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection

por Reau, Nancy, Kwo, Paul Y., Rhee, Susan, Brown, Robert S., Agarwal, Kosh, Angus, Peter, Gane, Edward, Kao, Jia‐Horng, Mantry, Parvez S., Mutimer, David, Reddy, K. Rajender, Tran, Tram T., Hu, Yiran B., Gulati, Abhishek, Krishnan, Preethi, Dumas, Emily O., Porcalla, Ariel, Shulman, Nancy S., Liu, Wei, Samanta, Suvajit, Trinh, Roger, Forns, Xavier
Publicado 2018

Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis

por Flamm, Steven, Mutimer, David, Asatryan, Armen, Wang, Stanley, Rockstroh, Jürgen, Horsmans, Yves, Kwo, Paul Y., Weiland, Ola, Villa, Erica, Heo, Jeong, Gane, Edward, Ryder, Stephen D., Welzel, Tania M., Ruane, Peter J., Agarwal, Kosh, Ng, Teresa I., Xue, Zhenyi, Lovell, Sandra S., Krishnan, Preethi, Kopecky‐Bromberg, Sarah, Trinh, Roger, Mensa, Federico J., Wyles, David L.
Publicado 2018